Elevated expression of HSP72 in the prefrontal cortex and hippocampus of rats subjected to chronic mild stress and treated with imipramine

Bielawski A.[1], Zelek-Molik A.[1], Rafa-Zabłocka K.[1], Kowalska M.[1], Gruca P.[2], Papp M.2 and Nalepa I.[1]

[1] Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland;

[2] Behavioral Pharmacology Laboratory, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland;

**Supplementary Table S1**. Lack of changes in expression of HSC70 mRNA in PFC and HIP of rats subjected to the CMS (stress) for 8 weeks and treated with IMI (10 mg/kg, ip) for 5 weeks determined by RTqPCR.

| Treatment | **HSC70** mRNA level [% of sal/sham control ± SEM] [1] | |
|---|---|---|
| | **PFC** | **HIP** |
| sham/sal | 100,00 ± 21,14 | 100,00 ± 7,69 |
| stress/sal | 88,95 ± 22,11 | 107,79 ± 3,66 |
| sham/IMI | 83,96 ± 14,87 | 91,40 ± 6,75 |
| stress/IMI resp | 96,63 ± 17,67 | 97,95 ± 4,17 |
| stress/IMI nonresp | 79,81 ± 5,98 | 107,40 ± 7,57 |
| *1 way ANOVA* | *F(4,25) = 0.88, p > 0.05* | *F(4,25) = 1.23, p >0.05* |

[1] Results are expressed as a percent of control (sham/sal) group ± standard error of mean (SEM); n = 6, stress/IMI resp – group of CMS rats that responded to IMI treatment (reversed anhedonia in sucrose test), stress/IMI nonresp – group of CMS rats nonresponding to IMI.

**Supplementary Table S2.** Lack of changes in expression of mRNAs of HSP90 family in the prefrontal cortex and HSP90A in the hippocampus of rats subjected to the CMS (stress) during 8 weeks and treated with IMI (10 mg/kg, ip) for 5 weeks determined by RTqPCR

| Treatment | mRNAs level [% of sal/sham control ± SEM] [1] | | |
|---|---|---|---|
| | **PFC** | | **HIP** |
| | **HSP90A** | **HSP90B** | **HSP90A** |
| sham/sal | 100,00± 7,39 | 100,00 ± 5,20 | 100,00 ± 1,80 |
| stress/sal | 100,80 ± 8,78 | 100,85 ± 5,86 | 104,98 ± 3,90 |
| sham/IMI | 109,89 ± 7,37 | 101,33 ± 4,24 | 98,07 ± 3,59 |
| stress/IMI resp | 101,45 ± 3,75 | 111,74 ± 6,95 | 102,90 ± 3,44 |
| stress/IMI nonresp | 97,86 ± 5,12 | 104,32 ± 6,17 | 100,62 ± 4,34 |
| *1 way ANOVA* | *F(4,25) = 0.47, p > 0.05* | *F(4,25) = 1.29, p > 0.05* | *F(4,25) = 0.58, p > 0.05* |

[1]Results are expressed as a percent of control (sham/sal) group ± standard error of mean (SEM); n = 6, stress/IMI resp – group of CMS rats that responded to IMI treatment (reversed anhedonia in sucrose test), stress/IMI nonresp – group of CMS rats nonresponding to IMI.

**Supplementary Table S3.** Lack of changes in mRNA expression of HSPA and HSPC families in Thal of rats subjected to the CMS (stress) for 8 weeks and treated with IMI (10 mg/kg, ip) for 5 weeks determined by RTqPCR.

| Treatment | mRNAs level in **Thal** [% of sal/sham control ± SEM][1] | | | |
|---|---|---|---|---|
| | **HSP72** | **HSC70** | **HSP90A** | **HSP90B** |
| sham/sal | 100,00 ± 7,50 | 100,00 ± 3,20 | 100,00 ± 11,30 | 100,00 ± 2,89 |
| stress/sal | 95,60 ± 8,43 | 109,00 ± 4,50 | 105,99 ± 5,38 | 99,01 ± 3,87 |
| sham/IMI | 99,80 ± 4,93 | 101,90 ± 4,70 | 108,00 ± 4,86 | 101,84 ± 4,12 |
| stress/IMI resp | 97,07 ± 9,94 | 112,00 ± 9,10 | 101,25 ± 7,51 | 97,88 ± 8,39 |
| stress/IMI nonresp | 115,74 ± 8,34 | 99,00 ± 5,00 | 100,72 ± 5,32 | 99,01 ± 7,58 |
| *1 way ANOVA* | $F(4,25) = 1.05$, $p > 0.05$ | $F(4,25) = 1.04$, $p > 0.05$ | $F(4,25) = 0.23$, $p > 0.05$ | $F(4,25) = 0.07$, $p > 0.05$ |

[1]Results are expressed as a percent of control (sham/sal) group ± standard error of mean (SEM); n = 6, stress/IMI resp – group of CMS rats that responded to IMI treatment (reversed anhedonia in sucrose test), stress/IMI nonresp – group of CMS rats nonresponding to IMI.